모아라이프플러스

142760KOSDAQ자연과학 및 공학 연구개발업

60.4 / 100

Reference Date: 2026-07-24

Financial Score22.5 / 40

News Sentiment16.9 / 25

Momentum7.0 / 20

Disclosure14.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Plunged 27.1% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Moalifeplus focuses on biopharmaceutical R&D using proprietary technologies (HumaMAX, MucoMAX), alongside consumer businesses such as health functional foods, cosmetics, and pet care products. Its γ-PGA-based functional ingredients are approved by the Korean FDA and the U.S. FDA, enabling global expansion through partnerships with Swiss companies and overseas exports of skincare brands.

Number of Employees

54people

Average Salary

39.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 43.644.0Point

PBR

0.52Industry Average 2.527.0Point

Half of industry avg (excellent)

ROE

-36.73Industry Average -32.093.5Point

In line with industry avg

Debt Ratio

1.91Industry Average 7.318.0Point

Half of industry avg (excellent)

Trend 2023~20250.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼21.3% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼12.6% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -13.1% (declining, 3yr)

Detailed News Sentiment

2 totalPositive 1Neutral 1Negative 0Average Sentiment Score 67.5

Neutral
韓, 구강 노쇠 진단 기준과 임상 지침 확립 안돼…"논의 필요"
The announcement regarding the lack of established standards for dental senescence diagnosis and clinical guidelines does not directly impact 모아라이프플러스's core business.
Positive
임강섭 복지부 과장 "혁신형 제약기업 글로벌 50대 도약 지원"
정부의 혁신형 제약기업 지원 정책 발표로 모아라이프플러스의 글로벌 경쟁력 강화 기대

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 379Won52-week high 1,85052-week low 374

1-month return0.0Point

1m -27.12% (strong drop)

Volume trend6.0Point

Volume increasing

Detailed Disclosure

13 totalPositive 2Neutral 11Negative 0

Neutral[기재정정]주요사항보고서(전환사채권발행결정)2026-07-20
Neutral[기재정정]주요사항보고서(주권관련사채권양도결정)2026-07-20
Neutral[첨부정정]주요사항보고서(전환사채권발행결정)2026-07-15
Neutral[기재정정]주주총회소집결의 (임시주주총회)2026-07-09
Positive[기재정정]최대주주변경을수반하는주식담보제공계약체결2026-07-09